New capecitabine schedule aims to improve quality of life in colorectal cancer
NCT ID NCT07215936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial compares a new 'dose-dense' schedule of capecitabine (one week on, one week off) against the standard regimen (two weeks on, one week off) in 100 people with colorectal cancer. The main goal is to see if the new schedule improves quality of life. The study is active but no longer recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- capecitabine
- What this could lead to
- If successful, this could offer a more convenient dosing schedule for capecitabine that maintains or improves quality of life for people with colorectal cancer.
- What could go wrong
- This is a small, early-phase trial with only 100 participants, so results may not apply to everyone. The new schedule may not be better than the standard one and could have different side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag university hospital
Sohag, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?